Opendata, web and dolomites

SYN1002

A New Therapeutic Option to Protect Central Nervous System against Acute Ischemic Stroke

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SYN1002 project word cloud

Explore the words cloud of the SYN1002 project. It provides you a very rough idea of what is the project "SYN1002" about.

feasibility    suitable    2026    health    acute    syn1002    peak    realize    deaths    immune    search    share    qualify    inflammatory    drug    successfully    initially    patients    treatments    positioning    biotech    perfect    16       intends    iia    solution    treat    strokes    framework    market    peptide    causing    damage    pharmaceutical    permanent    265m    deal    millions    multiple    substance    persons    approved    plasminogen    stoke    agent    six    world    400m    ais    ischemic    net    each    markets    match    50    experiencing    safety    larger    time    tolerability    rtpa    neuronal    safe    disability    stage    million    proof    plan    billion    draw    documenting    window    complement    thrombolytic    suffering    administered    company    recombinant    confirming    protect    licensing    applicable    indication    tissue    neuroprotective    limited    clinical    stroke    2017    sales    therapeutic    patient    pioneer    seed    industry    auto    doses    ongoing    2012    institutes    of    preclinical    anti    event    business    treatment    efficient    potent    pathologies    activator    orphit   

Project "SYN1002" data sheet

The following table provides information about the project.

Coordinator
ORPHIT 

Organization address
address: 1093 CHEMIN DES PLATEAUX FLEURIS RESIDENCES PANORA LA B
city: SAINT-LAURENT-DU-VAR
postcode: 6700
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.orphitpharma.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2018-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ORPHIT FR (SAINT-LAURENT-DU-VAR) coordinator 50˙000.00

Map

 Project objective

Each year, about 16 million strokes occur in the world causing millions of deaths and one third of patients experiencing permanent disability. The main treatment of stroke is thrombolytic agent recombinant tissue plasminogen activator (rtPA). Not all the patient can qualify for this treatment and it can be administered only in a limited time window. No existing drug is approved to protect against ongoing neuronal damage after the acute event. In this framework, our company, ORPHIT, a seed-stage biotech company, intends to be a pioneer by bringing clinical proof of concept of our peptide SYN1002 as suitable neuroprotective anti-inflammatory agent to treat stoke in acute phase that could be administered at multiple doses as complement to current thrombolytic treatments and also in patients who do not qualify for treatment with rtPA. This peptide is our lead product and has been initially developed as a potent anti-inflammatory substance in auto-immune pathologies with a clinical phase 1 study successfully documenting the safety and tolerability. Its properties make it a perfect match with current needs on Stroke treatment. Therefore, our solution is of interest for the pharmaceutical industry and health institutes who are currently in the search of a treatment that would be efficient and safe enough to be applicable to a larger part of the persons suffering from Stroke. The acute ischemic stroke (AIS) therapeutic market generated 400M€ in 2012 across the six major markets and is expected to reach 1.1 billion € by the end of 2017. SYN1002 sales at peak (2026) are expected to achieve 50% of market share, and a licensing deal at end of phase IIa would come out with a net present value of 265M€ for our company. In order to achieve this goal ORPHIT will realize a feasibility study aiming at strengthening SYN1002 preclinical package in AIS indication, confirming drug positioning through in depth market study, and draw a European business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYN1002" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYN1002" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More